Outlook Therapeutics, Inc.
OTLK
$1.37
-$0.02-1.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 62.26% | 9.06% | -66.12% | -58.95% | -67.00% |
| Gross Profit | -62.26% | -9.06% | 66.12% | 58.95% | 67.00% |
| SG&A Expenses | 35.48% | 12.25% | 12.19% | 12.62% | 14.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.75% | 34.97% | 12.13% | 11.82% | -27.20% |
| Operating Income | -73.75% | -34.97% | -12.13% | -11.82% | 27.20% |
| Income Before Tax | 9.10% | -27.78% | -55.88% | -178.21% | 26.70% |
| Income Tax Expenses | 0.00% | 0.00% | -22.22% | -22.22% | 0.00% |
| Earnings from Continuing Operations | 9.10% | -27.78% | -55.87% | -178.20% | 26.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.10% | -27.78% | -55.87% | -178.20% | 26.69% |
| EBIT | -73.75% | -34.97% | -12.13% | -11.82% | 27.20% |
| EBITDA | -73.74% | -34.87% | -12.13% | -11.93% | 27.11% |
| EPS Basic | -28.94% | -40.84% | -56.97% | -127.31% | 37.02% |
| Normalized Basic EPS | -32.47% | -43.39% | -57.46% | -111.78% | 41.76% |
| EPS Diluted | -99.04% | -99.51% | -112.17% | -127.33% | 37.00% |
| Normalized Diluted EPS | -36.34% | -46.56% | -60.39% | -111.78% | 41.76% |
| Average Basic Shares Outstanding | 65.32% | 48.32% | 32.05% | 14.81% | 16.43% |
| Average Diluted Shares Outstanding | 69.67% | 52.82% | 36.73% | 14.81% | 16.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |